BioNTech Results Presentation Deck

BNT162b2 Booster Dose Results in a Broad, Robust Neutralisation Response Booster dose could prolong protection and further increase breadth of protection against SARS-CoV-2 variants • 3rd dose strongly boosts neutralizing titers both in younger and older adults against Wild type > 5-8-fold • Delta variant > 5-11-fold Beta variant > 15-21-fold when comparing month 1 data after dose 2 or dose 3 ● 18 ● Wild type and Beta variant titers continue to increase comparing day 7/month 1 data after dose 2 versus dose 3 • Overall consistent tolerability profile Data being prepared for submission to regulatory authorities globally. Data submitted for publication. 50% serum neutralizing titer 104 10³ 10² 101 104 103. 10² 101 1.0 10 10 T T Day 1 Pre-Vax 0.30 310 497 1. . 150 #HE 0.78 M1PD2 18-55 y/o n= 11/gp 0.27 0.48 387 241 103 1 18-55 y/o n= 11/gp 1547 .. S 0.69 T Month 1 Month 8 Day 7 Post Dose 2 Post Dose 2 Post Dose 2 Post Dose 3 Post Dose 3 Day 7 Month 1 T 1754 1202 0.85 M1PD3 0.73 1321 AA 2119 . 1546 HEP. >> >* 1.0 10 10 Day 1 Pre-Vax 196 0.27 5:38 147 0.63 65-85 y/o n=12/gp 0.29 M1PD2 261 BH K 124 AAA 65-85 y/o n=12/gp 0.49 1613 2 T 1 n Month 1 Month 8 Day 7 Month 1 Day 7 Post Dose 2 Post Dose 2 Post Dose 2 Post Dose 3 Post Dose 3 0.67 0.92 1318 879 1479 0.77 M1PD3 2032 1567 LOD PRNTWT PRNT Beta GMR Beta/WT LOD *GMRDelta/WT PRNTWT PRNT Delta BIONTECH

View entire presentation